METHOTREXATE News

METHOTREXATE currently has 8 news articles, with 40 predicted indications.

This page combines the AI-predicted indications for METHOTREXATE with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (40):
- mantle cell lymphoma (99.0%)
- localized pagetoid reticulosis (99.0%)
- primary cutaneous T-cell lymphoma (99.0%)
- leukemia, lymphocytic, susceptibility to (99.0%)
- spondyloarthropathy (99.0%)
- precursor T-cell acute lymphoblastic leukemia (99.0%)
- juvenile arthritis due to defect in LACC1 (99.0%)
- non-Hodgkin lymphoma (99.0%)
- Burkitt lymphoma (99.0%)
- Langerhans cell histiocytosis (99.0%)
- granulomatous slack skin disease (99.0%)
- juvenile idiopathic arthritis (99.0%)
- lung neoplasm (99.0%)
- lymphoma (99.0%)
- acute lymphoblastic/lymphocytic leukemia (99.0%)
- gestational trophoblastic neoplasm (99.0%)
- parapsoriasis (99.0%)
- head and neck cancer (99.0%)
- upper aerodigestive tract neoplasm (99.0%)
- mycosis fungoides and variants (99.0%)
- acute lymphoblastic leukemia (disease) (99.0%)
- B-cell neoplasm (99.0%)
- psoriasis (99.0%)
- bone osteosarcoma (99.0%)
- female breast carcinoma (99.0%)
- folliculotropic mycosis fungoides (99.0%)
- rheumatoid arthritis (99.0%)
- lung cancer (99.0%)
- lymphosarcoma (99.0%)
- lymphoma, non-Hodgkin, familial (99.0%)
- pulmonary blastoma (99.5%)
- primary pulmonary lymphoma (99.5%)
- small cell lung carcinoma (99.4%)
- well-differentiated fetal adenocarcinoma of the lung (99.4%)
- Hodgkins lymphoma (99.3%)
- rhabdomyosarcoma (disease) (99.2%)
- chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation (99.2%)
- pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma (99.2%)
- parameningeal embryonal rhabdomyosarcoma (99.2%)
- botryoid-type embryonal rhabdomyosarcoma of the vagina (99.2%)